Track topics on Twitter Track topics that are important to you
Tricida, Inc. (NASDAQ: TCDA) today announced that it will report its second quarter 2018 financial results after the close of market on Wednesday, August 8, 2018. Tricida will h...
NewsTRC101 represents a first-in-class candidate for the treatment of metabolic acidosis, a common complication of CKD that can accelerate progression of kidney disease, increase the risk of muscle wa...
Tricida, a late-stage biotech company developing therapies for conditions associated with chronic kidney disease (CKD), filed late Monday with the Securities and Exchange Commission to raise up to $15...
Renal disease drug developer Tricida Inc. netted $206.7mm through its initial public offering of 11.7mm common shares at $19. (The company initially planned to sell 10.3mm shares at a range of $16-18....
Deciphera Pharmaceuticals has raised $97.16m through an underwritten public offering of 3.75 million shares of its common stock. The underwriters...Read More... The post Deals this week: Deciphera Pha...
Tricida Inc. entered a $100mm venture debt agreement with Hercules Capital. The company drew down an initial $25mm up front, with anther $50mm available subject to the achievement of certain milestone...
Tricida, Inc., is a pre-clinical-stage biopharmaceutical company focused on the discovery and development of first-in-class therapeutics. Tricidaâs lead program is TRC101, a ...
Tricida, Inc. is a pharmaceutical company focused on the development and commercialization of TRC101, a non-absorbed, orally-administered polymer designed to treat metabolic acido...
We have published hundreds of Tricida, Inc. news stories on BioPortfolio along with dozens of Tricida, Inc. Clinical Trials and PubMed Articles about Tricida, Inc. for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Tricida, Inc. Companies in our database. You can also find out about relevant Tricida, Inc. Drugs and Medications on this site too.